secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2026-07-22T21:03:59+00:00
Accession:  0001708599-26-000043
Event type: leadership
Sentiment:  positive
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics appoints Farrell Simon to Board of Directors
----------------------------------------------------------------

- Farrell Simon appointed to Serina's Board effective July 22, 2026; will serve on Audit and Compensation Committees.
- Simon is Chief Commercial Officer at Trevi Therapeutics (TRVI), helped raise over $400M from top-tier investors.
- Previously spent a decade at Pfizer in senior commercial and strategic roles.
- Serina's SER-252 Phase 1b registrational study is double-blind, placebo-controlled, with single and multiple ascending doses in Parkinson's patients.
- Simon's experience in commercial strategy and business development expected to support Serina's POZ platform and SER-252 development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859926000043/0001708599-26-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859926000043/ser-20260723xappointmentof.htm
  HTML page:      https://secwatch.observer/filing/0001708599-26-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer